logo-loader
viewImugene Ltd

Imugene adds key members to its scientific advisory board to advance company forward

Imugene Ltd (ASX:IMU) CEO Leslie Chong sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Imugene is an Australian biotechnology company with operations in the U.S. and in Europe, developing cancer immunotherapies targeting B-cell peptide vaccines.

Quick facts: Imugene Ltd

Price: 0.045 AUD

ASX:IMU
Market: ASX
Market Cap: $162.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene obtains FDA guidance for KEY-Vaxx immunotherapy clinical development...

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong updates Proactive Investors on the clinical-stage immuno-oncology company’s development of its KEY-Vaxx cancer vaccine.   The company had a pre-investigational new drug meeting with the US Food and Drug Administration...

on 03/19/2019

2 min read